According to Gram Research analysis, newly diagnosed MS patients show significantly higher fatigue and anxiety alongside specific blood changes indicating inflammation, damaged mitochondria, and nerve cell injury. A 2026 case-control study of 20 untreated MS patients found elevated inflammatory markers (IL-1β, IL-18, TNF-α), reduced nerve growth factors (BDNF and NGF), and signs of mitochondrial dysfunction compared to healthy controls. These blood markers, particularly S100β and neuron-specific enolase, may eventually help doctors understand why MS patients experience fatigue and anxiety, though larger studies are needed to confirm these findings.
Researchers studied 20 people newly diagnosed with relapsing-remitting multiple sclerosis (RRMS) and compared them to 20 healthy people. They found that MS patients had higher anxiety and fatigue levels, along with specific changes in their blood that suggest their bodies are experiencing inflammation, stress to their cells’ energy factories (mitochondria), and damage to nerve cells. These blood markers, including proteins like S100β and BDNF, could potentially help doctors understand why MS patients struggle with fatigue and anxiety, and might even help predict disease progression in the future.
Key Statistics
A 2026 case-control study of 20 newly diagnosed MS patients found significantly elevated inflammatory markers (IL-1β, IL-18, and TNF-α) in their blood compared to 20 healthy controls, suggesting inflammation plays a role in MS-related fatigue and anxiety.
Untreated MS patients in a 2026 study showed reduced levels of BDNF and NGF, nerve growth factors essential for nerve cell survival, along with signs of damaged mitochondria, indicating multiple biological systems are affected simultaneously.
A 2026 analysis of 40 participants found that MS patients had elevated S100β and neuron-specific enolase levels, proteins released when nerve cells are damaged, correlating with higher anxiety and fatigue scores.
Research from 2026 involving 20 MS patients identified increased mitochondrial DNA damage and abnormal patterns of cell survival proteins (higher Bax, lower Bcl-2), suggesting cells’ energy-producing structures are malfunctioning in untreated MS.
The Quick Take
- What they studied: Whether muscle fatigue and anxiety in newly diagnosed MS patients are connected to specific changes in blood markers related to inflammation, cell damage, and problems with how cells produce energy.
- Who participated: 20 people with newly diagnosed relapsing-remitting MS who hadn’t started treatment yet, plus 20 healthy people of similar age and gender for comparison.
- Key finding: MS patients showed significantly higher anxiety and fatigue scores, along with elevated inflammatory markers (IL-1β, IL-18, TNF-α) and signs of damaged mitochondria (the cell’s energy-producing structures) in their blood compared to healthy controls.
- What it means for you: Simple blood tests might one day help doctors identify why MS patients feel exhausted and anxious, potentially leading to better treatments. However, this is early research with a small group, so more studies are needed before these tests become routine clinical tools.
The Research Details
This was a case-control study, which means researchers compared two groups: people with newly diagnosed MS who hadn’t started treatment, and healthy people without MS. The researchers measured anxiety using a standard questionnaire (Beck Anxiety Inventory) and fatigue using two different scales. They then collected blood samples and analyzed them for dozens of different markers, proteins and molecules that indicate inflammation, cell damage, and problems with mitochondria (the parts of cells that make energy).
The study used several advanced laboratory techniques to measure these markers, including ELISA (a common blood test method), Western blotting (a way to detect specific proteins), and RT-PCR (a genetic testing method). This multi-layered approach allowed researchers to look at inflammation, oxidative stress (cellular damage from unstable molecules), mitochondrial dysfunction, nerve growth factors, and signs of nerve cell injury all at once.
Because this was a cross-sectional study (meaning researchers took a snapshot in time rather than following people over months or years), it shows associations between these factors but doesn’t prove that one causes the other.
Understanding the biological basis of fatigue and anxiety in MS is important because these symptoms significantly impact quality of life but are often difficult to treat. By identifying specific blood markers associated with these symptoms, researchers may eventually develop better diagnostic tools and targeted treatments. This approach, looking at peripheral (outside the brain) blood markers to understand central nervous system disease, is practical because blood tests are easier and less invasive than brain imaging.
Strengths: The study used rigorous laboratory methods and measured multiple related biological systems. The researchers matched control participants by age and sex, which reduces confounding factors. Limitations: The sample size is small (40 people total), which limits how much we can generalize findings. The study is cross-sectional, so it cannot establish cause-and-effect relationships. The study included only newly diagnosed, untreated patients, so findings may not apply to people already on MS medications. No information about the journal’s impact factor was provided, but the research appears methodologically sound for an exploratory study.
What the Results Show
Compared to healthy controls, MS patients showed significantly higher anxiety scores and fatigue scores on standardized measures. Their blood contained elevated levels of inflammatory molecules (IL-1β, IL-18, and TNF-α), which are proteins that trigger inflammation in the body. MS patients also showed increased expression of NLRP3 inflammasome, a cellular complex that activates inflammatory responses.
Most notably, MS patients showed multiple signs of mitochondrial dysfunction. Their blood had higher levels of reactive oxygen species (unstable molecules that damage cells), increased mitochondrial DNA damage, and abnormal patterns of proteins that control whether cells live or die (higher Bax, lower Bcl-2). They also showed reduced TFAM expression and increased Pink-1 and Parkin expression, markers suggesting their cells are trying to clean up damaged mitochondria.
Additionally, MS patients had elevated levels of S100β and neuron-specific enolase, which are proteins released when nerve cells are damaged. Conversely, they had lower levels of BDNF and NGF, growth factors that normally help nerve cells survive and function. The researchers found correlations suggesting these different biological problems are interconnected.
The study identified reduced vitamin D levels in MS patients, though this wasn’t the primary focus. The correlation analyses suggested that problems with mitochondrial function, inflammation, oxidative stress, and nerve cell damage are biologically linked, meaning they may be part of the same disease process rather than separate problems. This suggests that fatigue and anxiety in MS may stem from a combination of factors rather than a single cause.
Previous research has shown that MS involves inflammation and immune system dysfunction, but this study adds new information by demonstrating that untreated MS patients have specific mitochondrial problems and reduced nerve growth factors in their blood. The finding that anxiety and fatigue correlate with these biological markers aligns with emerging research suggesting that MS affects not just the nervous system but also cellular energy production. The identification of S100β and neuron-specific enolase as potential biomarkers builds on prior research showing these proteins indicate nerve damage.
The main limitation is the small sample size (20 MS patients), which means results may not apply to all MS patients and could be due to chance. The study only included newly diagnosed, untreated patients, so findings may differ in people already taking MS medications. The cross-sectional design means researchers cannot determine whether these blood marker changes cause fatigue and anxiety or result from them. The study didn’t measure other factors that might affect fatigue and anxiety, such as sleep quality, depression, or physical activity. Additionally, the study didn’t follow patients over time, so we don’t know if these biomarkers predict disease progression or treatment response.
The Bottom Line
Based on this research, there are no immediate clinical recommendations for patients. However, the findings suggest that future blood tests measuring S100β, BDNF, and mitochondrial markers could potentially help doctors better understand and manage fatigue and anxiety in MS. Patients experiencing fatigue and anxiety should discuss these symptoms with their neurologist, as current MS treatments and supportive therapies may help. Confidence level: Low to moderate: this is early-stage research requiring confirmation in larger studies.
People newly diagnosed with relapsing-remitting MS should be aware of this research as it may eventually lead to better tools for managing their symptoms. Healthcare providers treating MS patients should monitor this research area, as it may inform future diagnostic and treatment approaches. People with other neurological conditions involving fatigue and anxiety may also benefit from similar research. This research is less immediately relevant to people without MS or those with other MS types (primary progressive or secondary progressive).
This research is exploratory and preliminary. It typically takes 5-10 years for findings from small studies like this to translate into clinical tools. Patients should not expect changes in their care based on this single study. However, if these biomarkers are validated in larger studies, blood tests could potentially become available within 3-5 years.
Frequently Asked Questions
What causes fatigue and anxiety in multiple sclerosis patients?
A 2026 study found that MS-related fatigue and anxiety correlate with inflammation, damaged mitochondria (cell energy factories), reduced nerve growth factors, and nerve cell injury markers in the blood. These biological changes likely work together to cause these symptoms, though more research is needed to understand the exact mechanisms.
Can blood tests diagnose why I’m tired with MS?
Not yet. This 2026 research identified potential blood markers (S100β, BDNF, and mitochondrial markers) that correlate with fatigue and anxiety in MS, but these tests aren’t currently used clinically. Larger studies are needed before blood tests become standard diagnostic tools for MS-related fatigue.
Does MS treatment improve the blood markers associated with fatigue?
This study only examined untreated MS patients, so it doesn’t answer whether MS medications improve these blood markers. Future research should investigate whether starting MS treatment normalizes these inflammatory and mitochondrial markers and reduces fatigue and anxiety symptoms.
Are mitochondrial problems the main cause of MS fatigue?
A 2026 study found that untreated MS patients have mitochondrial dysfunction alongside inflammation and nerve damage, suggesting multiple biological problems contribute to fatigue. Mitochondrial dysfunction appears to be one important factor, but not the only cause, inflammation and reduced nerve growth factors also play roles.
Should I ask my doctor about these blood markers?
These biomarkers are currently research tools, not clinical tests. However, discussing fatigue and anxiety with your MS neurologist is important, as current MS treatments and supportive therapies can help. As this research develops, your doctor may eventually recommend these blood tests to personalize your treatment.
Want to Apply This Research?
- Track daily fatigue levels (0-10 scale) and anxiety symptoms (0-10 scale) alongside activity level and sleep hours. Over time, users can identify patterns and share data with their healthcare provider to discuss whether their symptoms correlate with disease activity.
- Users can set reminders to monitor and log their fatigue and anxiety daily, then review weekly trends. This creates awareness of symptom patterns and provides concrete data to discuss with their MS care team about whether current treatments are working.
- Establish a baseline of current fatigue and anxiety levels, then track changes monthly. If future blood tests become available that measure the biomarkers identified in this research, users could correlate their symptom tracking with biomarker results to understand their personal disease biology.
This research is preliminary and based on a small study of 40 people. The findings have not yet been confirmed in larger clinical trials and are not currently used for diagnosis or treatment decisions. If you have multiple sclerosis or are experiencing fatigue and anxiety, consult with your neurologist or healthcare provider before making any changes to your treatment plan. This article is for educational purposes and should not be considered medical advice. Blood tests mentioned in this research are not yet available for clinical use.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.
